Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-BTN3A agonistic monoclonal antibody ICT01

A humanized agonistic monoclonal antibody directed against butyrophilin subfamily 3 member A (BTN3A; CD277), with potential immunomodulating and antineoplastic activities. Upon administration, the anti-BTN3A agonistic monoclonal antibody ICT01 targets and binds to BTN3A present on epithelial and tumor cells. BTN3A binding may sensitize tumor cells to gamma 9 delta 2 (Vg9Vd2) T-cell killing. The Vg9Vd2 T cells secrete effector cytokines and exert a cytolytic effect on tumor cells. This may abrogate BTN3A-mediated tumor immunity and may enhance anti-tumor immune response. BTN3A, a member of the butyrophilin superfamily of immunomodulators, is upregulated in tumor cells.
Synonym:anti-BTN3A agonist monoclonal antibody ICT01
Code name:ICT 01
ICT-01
ICT01
Search NCI's Drug Dictionary